# Marzia Del Re

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/marzia-del-re/

## Facts

| Field | Value |
| --- | --- |
| Citations | 6,834 |
| Field | Cancer Genomics and Diagnostics |
| h-index | 46 |
| i10-index | 131 |
| Last Known Institution | Saint Camillus International University of Health and Medical Sciences |
| OpenAlex ID | https://openalex.org/A5030848899 |
| ORCID iD | 0000-0001-7343-6161 |
| Works | 267 |

## Researcher papers

- [Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan](https://scholariq.org/papers/rechallenge-for-patients-with-i-ras-i-and-i-braf-i-wild-type-metastatic/)
- [EGFR signaling pathway as therapeutic target in human cancers](https://scholariq.org/papers/egfr-signaling-pathway-as-therapeutic-target-in-human-cancers/)
- [The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients](https://scholariq.org/papers/the-detection-of-androgen-receptor-splice-variant-7-in-plasma-derived-exosomal/)
- [PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC](https://scholariq.org/papers/pd-l1-mrna-expression-in-plasma-derived-exosomes-is-associated-with-response-to/)
- [Clinical pharmacology of intravitreal anti-VEGF drugs](https://scholariq.org/papers/clinical-pharmacology-of-intravitreal-anti-vegf-drugs/)
- [<i>DPYD</i> IVS14+1G&gt;A and 2846A&gt;T Genotyping for the Prediction of Severe Fluoropyrimidine-Related Toxicity: A Meta-Analysis](https://scholariq.org/papers/i-dpyd-i-ivs14-1g-and-gt-a-and-2846a-and-gt-t-genotyping-for-the-prediction-of/)
- [Updates on liquid biopsy: current trends and future perspectives for clinical application in solid tumors](https://scholariq.org/papers/updates-on-liquid-biopsy-current-trends-and-future-perspectives-for-clinical/)
- [Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST)](https://scholariq.org/papers/liquid-biopsy-response-evaluation-criteria-in-solid-tumors-lb-recist/)
- [Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy](https://scholariq.org/papers/primary-resistance-to-osimertinib-due-to-sclc-transformation-issue-of-t790m/)
- [The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies](https://scholariq.org/papers/the-molecular-profiling-of-solid-tumors-by-liquid-biopsy-a-position-paper-of-the/)
- [From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC](https://scholariq.org/papers/from-the-beginning-to-resistance-study-of-plasma-monitoring-and-resistance/)

## Researcher topics

- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)

## Researcher university

- [Saint Camillus International University of Health and Medical Sciences](https://scholariq.org/institutions/saint-camillus-international-university-of-health-and-medical-sciences/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.